Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene?

One month into 2014 and this is where the biotech sector stands. Pretty darn good:

IBB Chart
IBB data by YCharts

If you're curious how January's performance stacks up to last year: The IBB closed January 2013 up 6.1% compared to a 5% gain for the S&P 500. 

The biggest surprise so far this year (at least to me) -- Celgene is stinking up the joint. Last years top-performing, large-cap biotech stock is this years worst by a wide margin. 

CELG Chart
CELG data by YCharts

What is ailing Celgene? I haven't heard any specific, other than investors may be rotating out in favor of Gilead, Biogen and Alexion Pharmaceuticals  (ALXN) because they provide higher earnings growth potential in the short term. 

If you know of any other reasons for Celgene's weakness, drop me a comment below. 


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

At End of May, Investors Signalling They May Stay Away

At End of May, Investors Signalling They May Stay Away

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever